{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:51:08Z","timestamp":1793836268860,"version":"4.6.1"},"reference-count":34,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2013,2,17]],"date-time":"2013-02-17T00:00:00Z","timestamp":1361059200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2013,4]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Robust evidence regarding medical intervention for symptomatic uncomplicated colonic diverticular disease (\n                      <jats:styled-content style=\"fixed-case\">DD<\/jats:styled-content>\n                      ) is sparse.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To investigate mesalazine (Salofalk granules) in this setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In a double\u2010blind, placebo\u2010controlled, multicentre, 6\u2010week trial, patients were randomised to mesalazine 1000\u00a0mg three times daily or placebo. Primary efficacy endpoint was change in lower abdominal pain to week 4 (baseline defined using pain score from 7\u00a0days pre\u2010treatment).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Median change in lower abdominal pain with mesalazine vs. placebo was \u221237 (\n                      <jats:italic>n\u00a0<\/jats:italic>\n                      =\u00a056) vs. \u221233 (\n                      <jats:italic>n\u00a0<\/jats:italic>\n                      =\u00a061) [\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.374; 95%\n                      <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n                      (\u221211; 4)] in the intent\u2010to\u2010treat (\n                      <jats:styled-content style=\"fixed-case\">ITT<\/jats:styled-content>\n                      ) population, and \u221241 (\n                      <jats:italic>n\u00a0<\/jats:italic>\n                      =\u00a040) vs. \u221233 (\n                      <jats:italic>n\u00a0<\/jats:italic>\n                      =\u00a051) [\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.053; 95%\n                      <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n                      (\u221218; 0)] in the per\u2010protocol (\n                      <jats:styled-content style=\"fixed-case\">PP<\/jats:styled-content>\n                      ) population, i.e. the primary endpoint was not significantly different.\n                      <jats:italic>Post hoc<\/jats:italic>\n                      adjustment for confounding factors (\u2018baseline pain intensity\u2019, \u2018baseline symptom score (Brodribb)\u2019, and \u2018localisation of diverticula in the descending colon\u2019) resulted in\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.111 [\n                      <jats:styled-content style=\"fixed-case\">ITT<\/jats:styled-content>\n                      , 95%\n                      <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n                      (\u221215.4; 1.6)] and\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.005 [\n                      <jats:styled-content style=\"fixed-case\">PP<\/jats:styled-content>\n                      , 95%\n                      <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n                      (\u221219.7; \u22123.5)]. Between\u2010group differences increased using pain score on day 1 as baseline, and reached significance for the\n                      <jats:styled-content style=\"fixed-case\">PP<\/jats:styled-content>\n                      population [mesalazine \u221242, placebo \u221226,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.010; 95%\n                      <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n                      (\u221225; \u22123)]. Median change in combined symptom score from baseline to week 4 was 257\u00a0mm with mesalazine vs. 198\u00a0mm with placebo [\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.064; 95%\n                      <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n                      (\u22123; 105)]. More placebo\u2010treated patients received analgesic\/spasmolytic concomitant medication (34.4% vs. mesalazine 21.4%), indicating improved pain relief with mesalazine (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.119). Safety was comparable.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      A daily dose of 3.0\u00a0g mesalazine may relieve pain during a symptomatic flare of uncomplicated\n                      <jats:styled-content style=\"fixed-case\">DD<\/jats:styled-content>\n                      . In this, the first placebo\u2010controlled double\u2010blind trial in acute uncomplicated\n                      <jats:styled-content style=\"fixed-case\">DD<\/jats:styled-content>\n                      , mesalazine showed promising therapeutic efficacy.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/apt.12248","type":"journal-article","created":{"date-parts":[[2013,2,18]],"date-time":"2013-02-18T15:28:49Z","timestamp":1361201329000},"page":"680-690","source":"Crossref","is-referenced-by-count":83,"title":["Randomised clinical trial: mesalazine (Salofalk granules) for uncomplicated diverticular disease of the colon \u2013 a placebo\u2010controlled study"],"prefix":"10.1111","volume":"37","author":[{"given":"W.","family":"Kruis","sequence":"first","affiliation":[{"name":"Innere Abteilung Ev Krankenhaus Kalk University of Cologne K\u00f6ln Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Meier","sequence":"additional","affiliation":[{"name":"Private Gastroenterology Practice Amberg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Schumacher","sequence":"additional","affiliation":[{"name":"Private Gastroenterology Practice Wolmirstedt Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Mickisch","sequence":"additional","affiliation":[{"name":"Private Gastroenterology Practice Mannheim Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Greinwald","sequence":"additional","affiliation":[{"name":"Clinical Research &amp; Development Department Dr. Falk Pharma GmbH Freiburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Mueller","sequence":"additional","affiliation":[{"name":"Clinical Research &amp; Development Department Dr. Falk Pharma GmbH Freiburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the German SAG\u201020 Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,2,17]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)15597-9"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s004649901007"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0b013e3181865f18"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1159\/000089779"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2007.03491.x"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2008.01879.x"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199805213382107"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0b013e318188adc1"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00384-008-0595-9"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2010.04530.x"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2982.2009.01308.x"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-007-9766-8"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mcg.0000225509.98041.4b"},{"key":"e_1_2_7_15_1","first-page":"916","article-title":"Mesalazine and\/or Lactobacillus casei in maintaining long\u2010term remission of symptomatic uncomplicated diverticular disease of the colon","volume":"55","author":"Tursi A","year":"2008","journal-title":"Hepatogastroenterology"},{"key":"e_1_2_7_16_1","first-page":"I70","article-title":"Rifaximin plus mesalazine followed by mesalazine alone is highly effective in obtaining remission of symptomatic uncomplicated diverticular disease","volume":"10","author":"Brandimarte G","year":"2004","journal-title":"Med Sci Monit"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0b013e3181a15864"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01564.x"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-006-9551-0"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(77)92112-2"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02555517"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(02)01383-9"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mcg.0000165651.17124.93"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1318.2009.01778.x"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1159\/000335695"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0b013e3181862ab1"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1318.2007.01238.x"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2168.1997.02576.x"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0b013e318188b1bc"},{"key":"e_1_2_7_30_1","first-page":"104","article-title":"Controversies with aminosalicylates in inflammatory bowel disease","volume":"4","author":"Lim WC","year":"2004","journal-title":"Rev Gastroenterol Disord"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1053\/jcgh.2003.50006"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2008.154302"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1159\/000335725"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1080\/00365520600780650"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.8688"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fapt.12248","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/apt.12248","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T11:58:26Z","timestamp":1700654306000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/apt.12248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,17]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["10.1111\/apt.12248"],"URL":"https:\/\/doi.org\/10.1111\/apt.12248","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,17]]}}}